PGPaul R. Gorry

Paul R. Gorry

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Paul R. Gorry has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Impact of HIV on Neuronal Health in the Brains of People with HIV

    by Thomas A. Angelovich, Jessica J. Kivinen, Sarah J. Byrnes, Paul R. Gorry, Melissa J. Churchill

    Despite effective viral suppression with antiretroviral therapy (ART), people with HIV (PWH) remain at increased risk of neurocognitive impairment and persistent neuroinflammation. Although neurons are not infected by HIV, they remain susceptible to the indirect effects of chronic infection, including exposure to viral proteins, inflammatory mediators, and glial dysfunction. The resulting neuronal injury is thought to contribute to the development and persistence of HIV-associated neurocognitive disorders in the ART era. This review examines the impact of chronic HIV infection on neuronal function, highlighting mechanisms of neuronal dysfunction driven by both viral-dependent and viral-independent pathways. We discuss the role of central nervous system viral reservoirs, neuroimmune interactions, and the neurotoxic effects of HIV proteins including Tat, gp120, and Nef. We further explore how chronic HIV infection influences synaptic integrity, neuronal metabolism, and age-related neurodegeneration. Finally, we highlight emerging biomarkers and therapeutic strategies aimed at preserving neuronal function. By integrating current evidence on both viral-dependent and viral-independent mechanisms of neuronal dysfunction, this review identifies critical knowledge gaps and future research priorities aimed at preserving neuron function and improving neurological outcomes in PWH.

  • Open Access

    Nanocapsules Comprised of Purified Protein: Construction and Applications in Vaccine Research

    by Ivana Skakic, Aya C. Taki, Jasmine E. Francis, Chaitali Dekiwadia, Thi Thu Hao Van, Carina C. D. Joe, Tram Phan, George Lovrecz, Paul R. Gorry, Paul A. Ramsland, et al.

    Nanoparticles show great promise as a platform for developing vaccines for the prevention of infectious disease. We have been investigating a method whereby nanocapsules can be formulated from protein, such that the final capsules contain only the cross-linked protein itself. Such nanocapsules are made using a silica templating system and can be customised in terms of size and porosity. Here we compare the construction and characteristics of nanocapsules from four different proteins: one a model protein (ovalbumin) and three from infectious disease pathogens, namely the influenza virus, Helicobacter pylori and HIV. Two of the nanocapsules were assessed further. We confirm that nanocapsules constructed from the urease A subunit of H. pylori can reduce subsequent infection in a vaccinated mouse model. Further, we show that capsules constructed from the HIV gp120 protein can be taken up by dendritic cells in tissue culture and can be recognised by antibodies raised against the virus. These results point to the utility of this method in constructing protein-only nanocapsules from proteins of varying sizes and isoelectric points.